MedTrace Logo

TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment

NCT00144417 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 433

Last updated 2011-08-03

No results posted yet for this study

Summary

This double-blind, randomized controlled trial evaluates moxifloxacin versus isoniazid in daily treatment during the first two months of treatment with rifampin, pyrazinamide and ethambutol for sputum smear-positive pulmonary tuberculosis.

Conditions

Interventions

DRUG

Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)

Moxifloxacin 400mg daily, 8 weeks

DRUG

isoniazid

isoniazid, oral, 300 mg, daily, 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Richard E Chaisson, MD · Johns Hopkins University

  • Susan E Dorman, MD · Johns Hopkins University

  • John L Johnson, MD · Case Western Reserve University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2007-06-30
Completion
2007-12-31

Countries

  • United States
  • Brazil
  • Canada
  • South Africa
  • Spain
  • Uganda

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00144417 on ClinicalTrials.gov